Phase 2 N=102 High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Pulmonary Toxicity — 32 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=77 Vitamin D Supplementation on Cardiovascular Risk Factors
Type 2 Diabetes
Primary: Blood Lipid — 213.08; 193.88 mg/dl
Phase 4 N=177 Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
Scoliosis
Primary: Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge) — 1775; 2116; 1531 ml
Phase 4 N=196 The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery
Blood Loss
Primary: Change in Hemoglobin on Day 0 Compared to Preoperatively — -1.277; -1.241 g/dL
N/A N=33 FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.
Chronic Kidney Disease · Acute Kidney Injury
Primary: Number of Subjects With Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function — 3; 4; 6; 1 participants
Phase 2 N=503 Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
Coronary Artery Disease (CAD)
Primary: Clinical Events Defined as the Composite of 30-day Death, MI, Repeat Revascularization, Catheter Thrombus, Stroke, Thrombocytopenia, Bailout Use of Glycoprotein IIb/IIIa…
Phase 1 N=23 Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
Cancer · Advanced Solid Malignancies
Primary: Number of Participants With Adverse Events — 4; 7; 10; 1 Participants
N/A N=241 Medtronic CoreValve Evolut R U.S. Clinical Study
Aortic Stenosis
Primary: All-cause Mortality at 30 Days by Percent — 2.5 percentage of partcipants
Phase 4 N=37 Effects of Ranolazine and Exercise on Daily Physical Activity Trial
Chronic Stable Angina
Primary: Change in Peak Oxygen Consumption (VO2 Max) — 0.03; 0.38; 0.9; 2.1 ml/kg/min — p=>0.05
Phase 2 N=410 Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
Herpes Zoster
Primary: Frequency of gE-specific Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Different Immunological Activation Markers — 231.82; 570.36; 2172.37; 2582.80…
Phase 2 N=184 Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Primary: Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study. — 4; 7; 6; 6 events
N/A N=38 Eosinophilic Airway Inflammation and Mepolizumab
Asthma
Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…
Phase 2 N=509 Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
Bacteremia
Primary: Cure Rate — 207; 209 Participants
Phase 2 N=15 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Merkel Cell Carcinoma
Primary: Percentage of Participants Who Experienced At Least 2-Fold Increase in Expression of IL-12 Protein in the Tumor Tissue After Intratumoral (IT) pIL-12 Injections and In…
N/A N=25 Electrical Stimulation for Hemiplegic Shoulder Pain
Stroke · Shoulder Pain
Primary: Brief Pain Inventory Short Form — 7.5; 7.6; 6.1; 6.8 units on a scale — p=0.04